Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 30 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.6M | 0.00% | 229.70K | −5.3% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DERM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Herskowitz NeilDirector | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Jun 30, 2026 | Toledano Miranda JayneDirector | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Jun 30, 2026 | Smith Justin AdamDirector | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Jun 24, 2026 | Rosenwald Lindsay ADirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Jun 24, 2026 | Pearce Michael CooperDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Jun 24, 2026 | Herskowitz NeilDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Jun 24, 2026 | Toledano Miranda JayneDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Jun 24, 2026 | Smith Justin AdamDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Apr 21, 2026 | Maraoui ClaudeChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 49.3K | — |
| Apr 21, 2026 | Benesch JosephChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 28.9K | — |
| Apr 21, 2026 | Alloush RamseyChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 46.9K | — |
| Aug 24, 2025 | Maraoui ClaudeChief Executive Officer | Conversion of Exercise of derivative security at price 0.06 per share. | 1.25M | $81.25K |
| Aug 4, 2025 | Rosenwald Lindsay ADirector | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Aug 4, 2025 | Pearce Michael CooperDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Aug 4, 2025 | Herskowitz NeilDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Aug 4, 2025 | Toledano Miranda JayneDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Aug 4, 2025 | Smith Justin AdamDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Jun 24, 2025 | Rosenwald Lindsay ADirector | Stock Award(Grant) at price 0.00 per share. | 7.2K | — |
| Jun 24, 2025 | Pearce Michael CooperDirector | Stock Award(Grant) at price 0.00 per share. | 7.2K | — |
| Jun 24, 2025 | Herskowitz NeilDirector | Stock Award(Grant) at price 0.00 per share. | 7.2K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.4 | -2.3 | -42.6 | 9.8 | 22.5 | 12.2 | -10.0 | 16.3 | -7.7 | -22.8 | −31.5% | ||
| 2025 | 16.4 | 23.7 | 4.8 | 25.8 | 8.6 | -10.9 | 2.4 | -1.9 | -1.2 | 14.0 | -0.6 | -4.5 | +97.2% |
| 2024 | -15.8 | -18.6 | -6.8 | 0.3 | 5.7 | 44.6 | -1.6 | -10.3 | 13.5 | 1.8 | 0.5 | -32.4 | −32.1% |
| 2023 | 19.3 | -27.1 | -6.0 | 10.2 | -30.9 | 33.1 | 21.4 | 10.9 | 28.0 | 23.7 | 26.0 | 34.9 | +200.0% |
| 2022 | -0.7 | -4.5 | -5.3 | -20.3 | 0.5 | -3.4 | -0.3 | -9.2 | -27.4 | -8.5 | -20.0 | 6.7 | −64.3% |
| 2021 | -32.0 | −32.0% |
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Buy / hold / sell counts